Publications by authors named "Enrica Franceschet"
Sustained virological response (SVR) after interferon-based therapy is associated with improvement of insulin resistance (IR) in HCV-infected patients. Few data are available in the direct-acting antivirals (DAAs) era, especially in cirrhotic patients. We prospectively evaluated the long-term effect of DAAs on IR.
View Article and Find Full Text PDFBackground & Aims: The eradication of Hepatitis C (HCV) infection by direct-acting antiviral (DAAs) agents has been linked to an amelioration of liver synthesis and regression of fibrosis. Although changes in number and type of circulating microvesicles (MVs) have been reported in cirrhosis, conclusive data on the effect of DAAs treatment on MVs profile in HCV cirrhotic patients remain scarce.
Methods: We measured the levels of endothelial, platelet and hepatocyte MVs, as well as MVs-expressing versican core protein (VCAN+) in patients with HCV-related cirrhosis at baseline, end of treatment (EOT), at 12, 24 and 48 weeks (W) after EOT by new generation flow cytometry.
Background & Aims: The long-term impact of sustained virological response (SVR) after direct-acting antivirals (DAAs) on the hypercoagulability associated with HCV cirrhosis is unknown. We longitudinally evaluated the effect of DAAs treatment on cirrhotic coagulopathy.
Methods: Pro- and anticoagulant factor levels and thrombin generation were assessed in patients with HCV-related cirrhosis at baseline, end of therapy (EOT), at 12, 24 and 48 weeks (W) after EOT.
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Liver Transpl
September 2017
Article Synopsis
- Concerns have been raised about the potential for increased recurrence of hepatocellular carcinoma (HCC) in patients undergoing direct-acting antiviral (DAA) therapy for hepatitis C while on the liver transplant waitlist.
- A study at Padua Liver Transplant Center compared HCC patients treated with DAAs to controls, finding similar dropout rates and progression in HCC characteristics between the two groups during follow-up.
- The results indicate that treating hepatitis C with DAAs does not significantly raise the risk of HCC recurrence or affect transplant eligibility, suggesting viral eradication may be safe for these patients.